Accelerating Cancer Therapeutics (ACT)
Accelerating Cancer Therapeutics (ACT) is a therapeutic development accelerator program focused on providing funding, education, partnership, and mentorship to Columbia Investigators, with a goal of advancing novel cancer therapies from the lab towards the clinic. Advice and project guidance will be provided by a steering committee of academic and industry experts in the field of drug development. Researchers are also encouraged to submit their funded research outcomes for publication in academic journals, as usual.
Request for Proposals
- Applications open:
- Monday, Sep. 13, 2021
- Applications due:
- Monday, Nov. 15, 2021
- Cohort announced:
- Wednesdays, 4-6:30PM, Jan - May
- Pitch Day:
2019-2020 Founders' Spotlights
Student Venture Associate Kush Mody interviewed cohort member Dr. Juan Arriaga of Meta Test. Based on research from the lab of Dr. Cory Abate-Shen which specializes in prostate cancer mouse models, Meta Test is a gene signature that will discern which patients are likely to develop metastases.
Student Venture Associate Grace Kim had a chance to virtually sit down with cohort member Dr. Yiping Han of FAP. Dr. Han's lab studies the role of bacterial pathogenesis in cancer.
Cumulative Success Metrics (ACT)
- 4 cycles administered
- 20 applications received
- 20 teams admitted to/went through accelerator
- 15 awards given
- Over $805K in funding awarded by ACT to teams
- $403K in funding awarded to teams by external sources